TM 30339

Drug Profile

TM 30339

Alternative Names: TM30339

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator 7TM Pharma
  • Class Obesity therapies; Peptides
  • Mechanism of Action Neuropeptide Y4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastrointestinal disorders; Obesity

Most Recent Events

  • 23 Apr 2010 Pharmacodynamics data from a Preclinical trial in Gastrointestinal disorders released by 7TM Pharma
  • 02 Sep 2008 Phase-I/II clinical trials in Obesity in USA (Parenteral)
  • 12 Mar 2007 Preclinical data added to the Obesity pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top